{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:17:05Z","timestamp":1779394625775,"version":"3.53.1"},"reference-count":94,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"no specific grant from any funding agency in the public, commercial, or not-for-profit sectors"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14712598.2021.1890713","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:36:03Z","timestamp":1613565363000},"page":"1215-1226","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma"],"prefix":"10.1080","volume":"21","author":[{"given":"Viktoria","family":"St\u00fchler","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Rausch","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3108","authenticated-orcid":false,"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital T\u00fcbingen, Eberhard-Karls-University T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"cit0001","unstructured":"Cancer of the kidney and renal pelvis - cancer stat facts. SEER. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Available from: 2019 Dec 24"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212528"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0054"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.022"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2257"},{"key":"cit0009","unstructured":"ESMO,eUpdate e renal cell carcinoma treatment recommendations. Available at: https:\/\/www.esmo.org\/guidelines\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renal-cell-carcinoma-treatment-recommendations-3. 2020 Nov 30"},{"key":"cit0010","volume-title":"Updated European Association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-na\u00efve metastatic clear-cell renal cell carcinoma","author":"Bedke J","year":"2021"},{"key":"cit0011","unstructured":"News release Merck, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma. Available from: Nov 10, 2020. https:\/\/bit.ly\/38yQ3o7."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.012963"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9"},{"key":"cit0014","first-page":"129","volume":"344","author":"Kandalaft LE","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4921"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2004.07.008"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"cit0019","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93411","volume":"2","author":"Siska PJ","year":"2017","journal-title":"JCI Insight"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2926"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-250985"},{"issue":"5","key":"cit0022","first-page":"1111","volume":"56","author":"Griffioen AW","year":"1996","journal-title":"Cancer Res"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3541"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-155"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.04.017"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4672"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065714"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0441-x"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604965"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/nm863"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1956"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.468"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30077"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0374"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-014-0160-8"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.989764"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84427"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.346"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0294-y"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71222-7"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8"},{"key":"cit0047","volume-title":"Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC)","author":"Bedke J","year":"2020"},{"key":"cit0048","unstructured":"Souli\u00e8res D, Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma: subgroup analysis from KEYNOTE-426 by prior nephrectomy. Presented at IKCS 2020: A Virtual Experience; 2020 Nov 6-7, 2020."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5080"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"cit0052","doi-asserted-by":"crossref","unstructured":"Pal S, Tsao CK, E.a. Suarez C,Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract 702O.","DOI":"10.1016\/j.annonc.2020.08.774"},{"key":"cit0053","unstructured":"ClinicalTrials.gov,A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04338269, Available from: 2020 Dec 12"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01598"},{"issue":"15","key":"cit0055","volume":"38","author":"Lee C-H","year":"2020","journal-title":"J clin oncol"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS706"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.618"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.5010"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4506"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.600"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01652"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS767"},{"issue":"15","key":"cit0063","volume":"37","author":"Zhang T","year":"2019","journal-title":"J clin oncol"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01327-7"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.609"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000891"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2136-x"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.2648"},{"key":"cit0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100030","volume":"6","author":"Aeppli S","year":"2021","journal-title":"ESMO Open"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.783"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4513"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5069"},{"issue":"15","key":"cit0076","volume":"38","author":"Lee J-L","year":"2020","journal-title":"J clin oncol"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.617"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4500"},{"key":"cit0079","unstructured":"Rini BI,ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal CellCarcinomaandSarcomatoid Histology: IMmotion151 Subgroup Analysis - Medical Oncologist Perspective Presented by: Brian I. Rini, Medical Oncologist, Cleveland Clinic, Cleveland, OH; Written by: Thenappan Chandrasekar, MD, Clinical Instructor, Thomas Jefferson University, @tchandra_uromd, @JEFFUrology, at the 2019 ASCO Annual Meeting #ASCO19, May 31-June 4, 2019, Chicago, IL USA, 2019."},{"issue":"5","key":"cit0080","first-page":"v356","volume":"30","author":"Choueiri TK","year":"2019","journal-title":"Ann Oncol"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920950199"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.031"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4576"},{"issue":"5","key":"cit0084","first-page":"v475","volume":"30","author":"Lee C","year":"2019","journal-title":"Ann Oncol"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.051"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5007"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071945"},{"issue":"8","key":"cit0090","first-page":"LBA31","volume":"29","author":"Rini BI","year":"2018","journal-title":". Annals of Oncology"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1092-z"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.101"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-4551(20)30283-6"},{"key":"cit0094","doi-asserted-by":"crossref","unstructured":"Vano Y, Elaidi R, B.M. et al. Results from the phase 2 BIOmarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in na\u00efve metastatic kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial (NCT02960906). Presented at: 2020 ESMO Congress; 2020 Sept 19-21; Virtual. Abstract: LBA25. 2020.","DOI":"10.1016\/j.annonc.2020.08.2254"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1890713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T20:33:37Z","timestamp":1671309217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1890713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":94,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14712598.2021.1890713"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1890713","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}